Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
XETRA:0QF
Holding DE:0QF?
Track your performance easily
0QF Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€34.30 - €156.54
Previous Close€40.27
Volume14.10K
Average Volume (3M)14.89K
Market Cap
€15.74B
Enterprise Value€10.34B
Total Cash (Recent Filing)$6.87B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Feb 20, 2025EPS Estimate
-€2.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.39
Shares Outstanding384,817,811
10 Day Avg. Volume13,649
30 Day Avg. Volume14,886
Standard Deviation0.19
R-Squared0.00302
Alpha-0.00606
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.30
Price to Sales (P/S)3.21
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit5.02
Enterprise Value/Ebitda-5.13
Forecast
1Y Price Target
€60.42Price Target Upside50.05% Upside
Rating ConsensusHold
Number of Analyst Covering19
Moderna News
PremiumMarket News
SPY ETF Update, 12/31/2024
PremiumMarket News
SPY ETF Update, 12/27/2024 
PremiumMarket News
SPY ETF Update, 12/24/2024 
PremiumMarket News
QQQ ETF Update, 12/23/2024 
PremiumMarket News
VOO ETF Update, 12/20/2024 Bulls Say, Bears Say
Bulls Say
Financial PerformanceModerna reported 3Q24 earnings that beat expectations, primarily driven by COVID-19 vaccine sales in the US which benefitted from a relatively earlier approval/launch.
Market PotentialCompany sees covid being a $2-3B durable base business given vaccination data from the last 2 years in the 'endemic' commercial market.
Product DevelopmentModerna plans to file next-gen COVID vaccine (mRNA-1283), COVID/flu combo vaccine (mRNA-1083) and label expansion in RSV (mRNA-1345) to high-risk adults 18 to 59 by YE24.
Bears Say
COVID-19 And RSV Vaccination TrendsUncertainty remains about future COVID and RSV vaccination trends, affecting sales projections.
Market Demand And GuidanceFocus has shifted to CMV interim analysis and COVID script trends, with concerns that declining COVID market demand and market share loss could impact future guidance.
Revenue And ProfitabilityStructural issues remain around real revenue growth, flu covid combo approval risk, high opex, and low visibility on any profits even by 2028.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.61% Insiders
20.34% Mutual Funds
0.03% Other Institutional Investors
39.09% Public Companies and
Individual Investors
0QF FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was €34.30 and its highest was €156.54 in the past 12 months.
What is Moderna’s market cap?
Currently, no data Available
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Feb 20, 2025 which is in 45 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Nov 07, 2024. The company reported €0.029 earnings per share for the quarter, beating the consensus estimate of -€1.75 by €1.779.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -€2.7.
How many shares outstanding does Moderna have?
Moderna has 384,817,800 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of €0.029 in its last earnings report, beating expectations of -€1.75. Following the earnings report the stock price went down -0.042%.
Which hedge fund is a major shareholder of Moderna?
Among the largest hedge funds holding Moderna’s share is Theleme Partners Llp. It holds Moderna’s shares valued at 483M.
---
Moderna Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€60.42 (50.05% Upside)
€60.42 (50.05% Upside)
Blogger Sentiment
Bullish
DE:0QF Sentiment 65%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.15%
12-Months-Change
Fundamentals
Return on Equity
-17.52%
Trailing 12-Months
Asset Growth
-18.75%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
0QF Company Deck
---
0QF Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in revenue growth, cost reduction, and pipeline progress. However, challenges remain in RSV sales, international market performance, and competitive pressures in the COVID vaccine market.Read More>---
0QF Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
0QF Stock 12 Month Forecast
Average Price Target
€60.42
▲(50.05% Upside)
Technical Analysis
Best Analysts Covering 0QF
1 Year
1 Year Success Rate
32/39 ratings generated profit
1 Year Average Return
-6.55%
assigned a sell rating last month
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 82.05% of your transactions generating a profit, with an average return of -6.55% per trade.
---